SANGAMO THERAPEUTICS, INC (SGMO) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, SANGAMO THERAPEUTICS, INC's filing signal turned positive.

Sangamo Therapeutics is a genomic medicine company focused on developing therapies for serious neurological diseases, leveraging its zinc finger epigenetic regulator and capsid engineering platforms. The company's core neurology programs target small fiber neuropathy and prion disease, with an investigational therapy for small fiber neuropathy (ST-503) having initiated Phase 1/2 clinical trials. Sangamo also has a gene therapy candidate for Fabry disease (isaralgagene civaparvovec) that has initiated a rolling BLA submission with the FDA, and a hemophilia A gene therapy candidate (giroctocogene fitelparvovec) for which it regained development rights. The company's technology platforms are designed to precisely target genetic or cellular causes of disease, and it has established collaborations with major biopharmaceutical companies like Genentech, Astellas, and Eli Lilly.

Revenues are primarily derived from collaboration agreements, including upfront license fees, milestone payments, research services, and royalties from license agreements.